

01-26

JP



DOCKET NO.: C1039.70073US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No.: 10/743,625
Confirmation No.: 9416
Filed: December 22, 2003
For: IMMUNOSTIMULATORY NUCLEIC ACID
Examiner: Nita M. Minnifield
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 23rd day of January, 2007.

Emily E. Zukauskas
Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check in the amount of \$180 is enclosed to cover the filing fee. If the fee is insufficient, the balance may be charged to Deposit Account 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By: *Helen C. Lockhart*
Helen C. Lockhart, Ph.D., Reg. No.: 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1039.70073US00
Date: January 23 2007
xNDDx




DOCKET NO.: C1039.70073US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No.: 10/743,625
Confirmation No.: 9416
Filed: December 22, 2003
For: IMMUNOSTIMULATORY NUCLEIC ACID
Examiner: Nita M. Minnifield
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 23rd day of January, 2007.


Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
10/811,226	03-26-2004	Wagner et al.	*C1041.70005US01
11/503,377	08-11-2006	Krieg et al.	*C1039.70061US01
11/507,079	08-18-2006	Krieg et al.	*C1039.70035US04
11/526,197	09-22-2006	Krieg et al.	*C1039.70048US23
11/526,896	09-22-2006	Bratzler et al.	*C1037.70013US03
11/542,845	10-04-2006	Krieg et al.	*C1037.70048US01
11/543,314	10-04-2006	Lipford et al.	*C1041.70036US02
11/595,823	11-10-2006	Wagner et al.	*C1041.70035US01
11/598,207	11-10-2006	Krieg et al.	*C1039.70048US24
11/603,978	11-22-2006	Forsbach et al.	*C1041.70053US02
11/629,106	12-08-2006	Lipford et al.	*C1041.70027US01
11/645,106	12-22-2006	Krieg et al.	*C1039.70083US17

*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following are remarks concerning the other information cited:

The instant patent application derives priority from US 6,207,646 B1, which was involved in an Interference (Interference No. 105,171). In view of the priority, Applicants have included on the attached 1449 a listing of all of the motions filed, the judgment rendered by the

Board of Patent Appeals and Interferences, appeal briefs, and appeal decision, which considered the 35 U.S.C. §135(b)(1) motion dispositive. Copies of these documents were previously submitted in Serial No. 09/818,918, filed March 27, 2001, to which the instant application derives priority. If the Examiner would like any additional information on this subject, she is encouraged to contact Applicant's representative at the number listed below.

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 10/743,625
Conf. No.: 9416


- 4 -

Art Unit: 1645


Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: 
Helen C. Lockhart, Ph.D., Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1039.70073US00
Date: January 23, 2007
xNDDx



FORM PTO/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
		FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
		APPLICANT: Krieg et al.			
		GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	1	of	19		

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,112,605		Jardieu	05-12-1992
		5,498,410		Gleich	03-12-1996
		5,679,647		Carson et al.	10-21-1997
		5,681,555		Gleich	10-28-1997
		5,908,620		Tu et al.	06-01-1999
		5,955,059		Gilchrest et al.	09-21-1999
		5,994,315		Nyce et al.	11-30-1999
		6,025,339		Nyce	02-15-2000
		6,040,296		Nyce	03-21-2000
		6,090,791		Sato et al.	07-18-2000
		6,096,721		McMichael	08-01-2000
		6,100,244		McMichael	08-08-2000
		6,174,872	B1	Carson et al.	01-16-2001
		6,221,882		Macfarlane	04-24-2001
		6,339,630		Macfarlane	06-04-2002
		6,406,705	B1	Davis et al.	06-18-2002
		6,426,336	B1	Carson et al.	07-30-2002
		6,479,504		Macfarlane et al.	11-12-2002
		6,521,637		Macfarlane	02-18-2003
		6,727,230	B1	Hutcherson et al.	04-27-2004
		6,797,276	B1	Glenn et al.	09-28-2004
		6,815,429	B2	Agrawal	11-09-2004
		6,821,957	B1	Krieg et al.	11-23-2004
		6,843,992	B2	Diamond	01-18-2005
		6,887,464	B1	Coleman et al.	05-03-2005
		6,936,261	B2	Granoff et al.	08-30-2005
		6,943,240		Bauer et al.	09-13-2005
		6,949,520		Hartmann et al.	09-27-2005
		6,951,845		Carson et al.	10-04-2005
		7,001,890		Wagner et al.	02-26-2006
		2001-0044416	A1	McCluskie et al.	11-22-2001
		2002-0064515	A1	Krieg et al.	05-30-2002
		2003-0087848	A1	Bratzler et al.	05-08-2003

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00			
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield			
Sheet	2	of	19						

		2002-0091097	A1	Bratzler et al.	07-11-2002
		2003-0091599	A1	Davis et al.	05-15-2003
		2002-0164341	A1	Davis et al.	11-07-2002
		2002-0165178	A1	Schetter et al.	11-07-2002
		2002-0198165	A1	Bratzler et al.	12-26-2002
		2003-0026782	A1	Krieg et al.	02-06-2003
		2003-0026801	A1	Weiner et al.	02-06-2003
		2003-0027782	A1	Carson et al.	02-06-2003
		2003-0050261	A1	Krieg et al.	03-13-2003
		2003-0050268	A1	Krieg et al.	03-13-2003
		2003-0055014	A1	Bratzler	03-20-2003
		2003-0100527	A1	Krieg et al.	05-29-2003
		2003-0104523	A1	Bauer et al.	06-05-2003
		2003-0125279	A1	Junghans et al.	07-03-2003
		2003-0139364	A1	Krieg et al.	07-24-2003
		2003-0148316	A1	Lipford et al.	08-07-2003
		2003-0148976	A1	Krieg et al.	08-07-2003
		2003-0166001	A1	Lipford	09-04-2003
		2003-0181406	A1	Schetter et al.	09-25-2003
		2003-0191079	A1	Krieg et al.	10-09-2003
		2003-0125279	A1	Junghans et al.	07-03-2003
		2003-0148976	A1	Krieg et al.	08-07-2003
		2003-0212026	A1	Krieg et al.	11-13-2003
		2003-0224010	A1	Davis et al.	12-04-2003
		2003-0232074	A1	Lipford et al.	12-18-2003
		2003-0232856	A1	Macfarlane	12-18-2003
		2004-0006010	A1	Carson et al.	01-08-2004
		2004-0009949	A1	Krieg	01-15-2004
		2004-0030118	A1	Wagner et al.	02-12-2004
		2004-0053880	A1	Krieg	03-18-2004
		2004-0067902	A9	Bratzler et al.	04-08-2004
		2004-0067905	A1	Krieg	04-08-2004
		2004-0087534	A1	Krieg et al.	05-06-2004
		2004-0087538	A1	Krieg et al.	05-06-2004
		2004-0092468	A1	Schwartz et al.	05-13-2004
		2004-0106568	A1	Krieg et al.	06-03-2004

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00			
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield			
Sheet	3	of	19						

		2004-0131628	A1	Bratzler et al.	07-08-2004
		2004-0132685	A1	Krieg et al.	07-08-2004
		2004-0142469	A1	Krieg et al.	07-22-2004
		2004-0143112	A1	Krieg et al.	07-22-2004
		2004-0152649	A1	Krieg	08-05-2004
		2004-0152656	A1	Krieg et al.	08-05-2004
		2004-0152657	A1	Krieg et al.	08-05-2004
		2004-0162258	A1	Krieg et al.	08-19-2004
		2004-0162262	A1	Krieg et al.	08-19-2004
		2004-0167089	A1	Krieg et al.	08-26-2004
		2004-0171150	A1	Krieg et al.	09-02-2004
		2004-0171571	A1	Krieg et al.	09-02-2004
		2004-0181045	A1	Krieg et al.	09-16-2004
		2004-0234512	A1	Wagner et al.	11-25-2004
		2004-0235770	A1	Davis et al.	11-25-2004
		2004-0235774	A1	Bratzler et al.	11-25-2004
		2004-0235777	A1	Wagner et al.	11-25-2004
		2004-0235778	A1	Wagner et al.	11-25-2004
		2004-0266719	A1	McCluskie et al.	12-30-2004
		2005-0004062	A1	Krieg et al.	01-06-2005
		2005-0009774	A1	Krieg et al.	01-13-2005
		2005-0032734	A1	Davis et al.	02-10-2005
		2005-0037403	A1	Krieg et al.	02-17-2005
		2005-0037985	A1	Krieg et al.	02-17-2005
		2005-0042203	A1	Davis et al.	02-24-2005
		2005-0049215	A1	Krieg et al.	03-03-2005
		2005-0054601	A1	Wagner et al.	03-10-2005
		2005-0059619	A1	Krieg et al.	03-17-2005
		2005-0059625	A1	Krieg et al.	03-17-2005
		2005-0070491	A1	Krieg et al.	03-31-2005
		2005-0075302	A1	Hutcherson et al.	04-07-2005
		2005-0100983	A1	Bauer et al.	05-12-2005
		2005-0101554	A1	Krieg et al.	05-12-2005
		2005-0119273	A1	Lipford et al.	06-02-2005
		2005-0130911	A1	Uhlmann et al.	06-16-2005
		2005-0169888	A1	Hartman et al.	08-04-2005

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00			
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield			
Sheet	4	of	19						

		2005-0171047	A1	Krieg et al.	08-04-2005
		2005-0181422	A1	Bauer et al.	08-18-2005
		2005-0182017	A1	Krieg	08-18-2005
		2005-0197314	A1	Krieg et al.	09-08-2005
		2005-0215500	A1	Krieg et al.	09-29-2005
		2005-0215501	A1	Lipford et al.	09-29-2005
		2005-0233995	A1	Krieg et al.	10-20-2005
		2005-0233999	A1	Krieg et al.	10-20-2005
		2005-0239732	A1	Krieg et al.	10-27-2005
		2005-0239733	A1	Jurk et al.	10-27-2005
		2005-0239734	A1	Uhlmann et al.	10-27-2005
		2005-0239736	A1	Krieg et al.	10-27-2005
		2005-0245477	A1	Krieg et al.	11-03-2005
		2005-0244379	A1	Krieg et al.	11-03-2005
		2005-0244380	A1	Krieg et al.	11-03-2005
		2005-0250726	A1	Krieg et al.	11-10-2005
		2005-0256073	A1	Lipford et al.	11-17-2005
		2005-0267057	A1	Krieg	12-01-2005
		2005-0267064	A1	Krieg et al.	12-01-2005
		2005-0277604	A1	Krieg et al.	12-15-2005
		2005-0277609	A1	Krieg et al.	12-15-2005
		2006-0003962	A1	Ahluwalia et al.	01-05-2006
		2006-0019239	A1	Ivins et al.	01-26-2006
		2006-0019909	A1	Agrawal et al.	01-26-2006
		2006-0019916	A1	Krieg et al.	01-26-2006
		2006-0019923	A1	Davis et al.	01-26-2006
		2006-0058251	A1	Krieg et al.	03-16-2006
		2006-0089326	A1	Krieg et al.	04-27-2006
		2006-0094683	A1	Krieg et al.	05-04-2006
		2006-0140875	A1	Krieg et al.	06-29-2006
		2006-0154890	A1	Bratzler et al.	07-13-2006
		2006-0172966	A1	Lipford et al.	08-03-2006
		2006-0188913	A1	Krieg et al.	08-24-2006
		2006-0211639	A1	Bratzler et al.	09-21-2006
		2006-0211644	A1	Krieg et al.	09-21-2006
		2006-0229271	A1	Krieg et al.	10-12-2006

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	5	of	19				

		2006-0241076	A1	Uhlmann et al.	10-26-2006
		2006-0246035	A1	Ahluwalia et al.	11-02-2006
		2006-0286070	A1	Hartmann et al.	12-21-2006
		2006-0287263	A1	Davis et al.	12-21-2006
		2007-0009482	A1	Krieg et al.	01-11-2007
		2007-0010470	A1	Krieg et al.	01-11-2007

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	0 766 571	B1	Steris Corporation	04-09-1997	
		WO	96/32138	A1	Milkhaus Laboratory	10-17-1996	
		WO	99/52549	A1	Smithkline Beecham Biologicals S.A.	10-29-1999	
		WO	00/16804	A1	Dynavax Technologies Corporation	03-30-2000	
	*	WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
		WO	01/45750	A1	Regents of the University of California	06-28-2001	
		WO	01/68144	A2	Dynavax Technologies Corporation	09-20-2001	
		WO	03/000232	A2	Dynavax Technologies Corporation	01-03-2003	
		WO	03/094963	A2	INEX Pharmaceuticals Corp.	11-20-2003	
		WO	03/101375	A2	Immunotech SA	12-11-2003	
	*	WO	2004/007743	A2	Coley Pharmaceutical GmbH	01-22-2004	
		WO	2004/026888	A2	Coley Pharmaceutical GmbH	04-01-2004	
		WO	2004/039829	A2	Coley Pharmaceutical Group, Ltd.	05-13-2004	
		WO	2004/094671	A2	Coley Pharmaceutical GmbH	11-04-2004	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] Allergen Nomenclature, List of Allergens (as of March 12, 2004).	
		[No Author Listed] Expert panel report 2: Guidelines for the diagnosis and management of asthma – Clinical practice guidelines. National Institutes of Health Publication. 1997 Jul; No. 97-4051:iii-79.	
		[No Author Listed] DNA is the primary genetic material. in Recombinant DNA, Second Edition. Watson et al., editors. Scientific American Books, New York. p24-5, 147. Exhibit 1003.	
		[No Author Listed] Definitions. in The Dictionary of Immunology, Fourth Edition. Herbert et al., editors. Academic Press, 1995. p10. Exhibit 1004.	
		[No Author Listed] http://www.doctorfungus.com/the_fungi/Cryptococcus.htm . Exhibit 1029.	
		[No Author Listed] http://www.doctorfungus.com/the_fungi/Blastomyces.htm . Exhibit 1030.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	6	of	19				

		[No Author Listed] http://www.doctorfungus.com/the_fungi/Alternaria.htm . Exhibit 1031.	
		[No Author Listed] http://www.cancer.gov/newscenter/pressreleases/cancervaccines/print . Exhibit 1042.	
		[No Author Listed] http://www.cancer.gov/clinicaltrials/learning/cancervaccines/print . Exhibit 1043.	
		[No Author Listed] Recombinant DNA Technology. in Molecular Biology of the Cell. Alberts et al., editors. Garland Publishing, Inc. 1983. Exhibit 2027.	
		[No Author Listed] Definitions. in Dorland's Illustrated Medical Dictionary, Twenty-sixth Edition. W.B. Saunders Company, 1981. Exhibit 2032.	
		[No Author Listed] Macromolecules in Prokaryotic and Eukaryotic Cells. in Molecular Cell Biology, Darnell et al, Editors. W.H. Freeman and Company, 1986. Exhibit 2033.	
		[No Author Listed] Definitions. in Immunology, Roitt et al., Editors. Gower Medical Publishing Company, 1985. Exhibit 2035.	
		[No Author Listed] Definitions. in Webster's New Collegiate Dictionary. The G&C Merriam Company, 1981. p287. Exhibit 2070.	
		[No Author Listed] http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Cancer_Vaccines_Active_Specific_Immunotherapies.asp . Exhibit 2072.	
		[No Author Listed] http://www.plwc.org/plwc/mainconstructor . Exhibit 2073.	
		[No Author Listed] http://www.icare.org/treatment/tcwvt4.htm . Exhibit 2074.	
	*	ABED et al., Interferon-gamma regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-mediated inhibition of B cell differentiation. Cell Immunol. 1994 Feb;153(2):356-66.	
	*	AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.	
		ALM et al., Early BCG vaccination and development of atopy. Lancet. 1997 Aug 9;350(9075):400-3.	
		ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
	*	ASKENASE et al., Gee whiz: CpG DNA allergy therapy! J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):37-40.	
		ASKEW et al., CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15;165(12):6889-95.	
		BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. Immunology. 1999 Aug;97(4):699-705.	
		BAUER et al., Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42.	
		BERG et al., Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest. 1995 Nov;96(5):2339-47.	
		BLANCHARD et al., Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. J Immunol. 1986 Feb 1;136(3):963-70. Abstract Only.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	7	of	19				

	*	BOCHNER et al., Advances in mechanisms of allergy. J Allergy Clin Immunol. 2004 May;113(5):868-75.	
		BOHLE et al., Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol. 1999 Jul;29(7):2344-53.	
		BOUSHEY et al., Targets for asthma therapy. Allerg Immunol (Paris). 2000 Nov;32(9):336-41. Abstract Only.	
		BRAZOLOT-MILLAN et al., CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8.	
		BROIDE et al., Modulation of asthmatic response by immunostimulatory DNA sequences. Springer Semin Immunopathol. 2000;22(1-2):117-24.	
		BROIDE et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol. 1998 Dec 15;161(12):7054-62.	
		BRUNNER et al., Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000 Dec 1;165(11):6278-86.	
		CAMPBELL et al., Allergen immunotherapy: novel approaches in the management of allergic diseases and asthma. Clin Immunol. 2000 Dec;97(3):193-202.	
		CAPRON et al., Immunologic aspects of schistosomiasis. Annu Rev Med. 1992;43:209-18. Review. Exhibit 2068.	
	*	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	
		CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
		CHIANG et al., Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am J Respir Crit Care Med. 2003 Sep 1;168(5):575-80.	
		CHISHOLM et al., Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol. 2004 Mar;113(3):448-54.	
		CHOUDHURY et al., In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J Immunol. 2002 Nov 15;169(10):5955-61.	
		COCKCROFT et al., Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol. 1987 May;79(5):734-40.	
		COOPER et al., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov;24(6):693-701.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00		
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield		
Sheet	8	of	19					

		CRETICOS et al., New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA. Immunol Allergy Clin North Am. 2004 Nov;24(4):569-81.	
		CROFT et al., Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med. 1994 Nov 1;180(5):1715-28.	
		D'ANDREA et al., Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993 Sep 1;178(3):1041-8.	
		DAVIS, Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol. 2000;247:171-83.	
	*	DUNN et al., The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-60.	
	*	DURHAM et al., Immunotherapy and allergic inflammation. Clin Exp Allergy. 1991 Jan;21 Suppl 1:206-10.	
		FELESZKO et al., Toll-like receptors--novel targets in allergic airway disease (probiotics, friends and relatives). Eur J Pharmacol. 2006 Mar 8;533(1-3):308-18.	
		FITCH et al., The effect of an oral phosphodiesterase (PDE) 4 inhibitor bay 19-8004 in primate asthma models. American Thoracic Society. 2000. A52 Poster A94.	
	*	FRANCOIS et al., Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. Clin Immunol Immunopathol. 1988 Sep;48(3):297-306.	
		FRIEDBERG et al., Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005 Jan 15;105(2):489-95.	
	*	FRISSORA et al., IFN-gamma-mediated inhibition of antigen receptor-induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor. Eur J Immunol. 2003 Apr;33(4):907-12.	
		GIBSON et al., Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res. 1995 Jun;15(6):537-45.	
		GRUNIG, G. et al., Molecular regulation of Th2 immunity by dendritic cells. Pharmacol Ther. 2005 Apr;106(1):75-96.	
		GUNDEL et al., Antigen-induced mediator release in primates. Am Rev Respir Dis. 1991 Jul;144(1):76-82.	
		GUNDEL et al., Repeated antigen inhalation results in a prolonged airway eosinophilia and airway hyperresponsiveness in primates. J Appl Physiol. 1990 Feb;68(2):779-86.	
		HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999 May;6(5):893-903.	
		HARTMANN et al., Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000 Jan 15;164(2):944-53.	
		HARTMANN et al., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000 Feb 1;164(3):1617-24.	
		HARTMANN et al., CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9305-10.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00		
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield		
Sheet	9	of	19					

		HEEG et al., CpG DNA as a Th1 trigger. <i>Int Arch Allergy Immunol.</i> 2000 Feb;121(2):87-97.	
	*	HEMMI et al., Toll-like receptor recognizes bacterial DNA. <i>Nature.</i> 2000 Dec 7;408(6813):740-5.	
		HEMMI et al., The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. <i>J Immunol.</i> 2003 Mar 15;170(6):3059-64.	
		HERZ et al., BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. <i>J Allergy Clin Immunol.</i> 1998 Nov;102(5):867-74.	
		HOGG et al., The pathology of asthma. <i>APMIS.</i> 1997 Oct;105(10):735-45.	
		HOPKIN et al., Curbing the CpGs of Bacterial and Viral DNA. <i>BioMedNet.</i> 1999 Jun25; Issue 57.	
		HORNER et al., Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. <i>J Allergy Clin Immunol.</i> 2002 Nov;110(5):706-12.	
		HORNER et al., Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. <i>J Allergy Clin Immunol.</i> 2002 Sep;110(3):413-20.	
		HORNER et al., Chapter 22: DNA-based immunotherapeutics for allergic disease. From: <i>Microbial DNA and Host Immunity.</i> 2002:279-87.	
		HOWARTH et al., Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. <i>Am Rev Respir Dis.</i> 1985 Nov;132(5):986-92.	
		HUMLOVA et al., [Bacteria and their role in allergic diseases] <i>Cas Lek Cesk.</i> 2004;143(1):21-5. Review. Czech. English Abstract Only.	
		IHO et al., Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro. <i>J Immunol.</i> 1999 Oct 1;163(7):3642-52.	
		IKEDA et al., Microbial DNA and Host Immunity. Chapter 23: Immunostimulatory DNA for allergic asthma. 2002: 289-99.	
		INFANTE-DUARTE et al., Th1/Th2 balance in infection. <i>Springer Semin Immunopathol.</i> 1999;21(3):317-38.	
		JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. <i>J Immunol.</i> 1998 Sep 15;161(6):3042-9.	
		JAKOB et al., Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. <i>Int Arch Allergy Immunol.</i> 1999 Feb-Apr;118(2-4):457-61.	
	*	JILEK et al., Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. <i>J Immunol.</i> 2001 Mar 1;166(5):3612-21.	
		JONES et al., Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. <i>Can J Physiol Pharmacol.</i> 1995 Feb;73(2):191-201.	
		KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from <i>Mycobacterium bovis</i> BCG complexed with poly-L-lysine and carboxymethylcellulose. <i>Jpn J Med Sci Biol.</i> 1990 Oct;43(5):171-82.	

EXAMINER:	DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	10	of	19				

	KITAGAKI et al., CpG Oligodeoxynucleotides in Asthma. In: Microbial DNA and Host Immunity. 2002. Chapter 24: 301-14.	
	KLINMAN et al., Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol. 2002 Jul;283(1):L170-9.	
	KLINMAN et al., Effects of CpG DNA on Th1/Th2 balance in asthma. Curr Top Microbiol Immunol. 2000;247:211-25.	
	KLINMAN et al., Immune recognition of foreign DNA: a cure for bioterrorism? Immunity. 1999 Aug;11(2):123-9.	
	KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol. 1997 Apr 15;158(8):3635-9.	
	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000 Jun;13(5):289-96.	
	KOHAMA et al., Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. J Allergy Clin Immunol. 1999 Dec;104(6):1231-8.	
	KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 1;162(3):1611-7.	
	KRANZER et al. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology. 2000 Feb;99(2):170-8.	
	KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996: 116.	
	KRIEG et al., Infection. In McGraw Hill Book. 1996: 242-3.	
	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 1;161(5):2428-34.	
	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.	
	KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20.	
	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	
	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	11	of	19				

		KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
		KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.	
		KRIEG et al., Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb;3(1):15-24.	
		KRIEG et al., Chapter 7: CpG oligonucleotides as immune adjuvants. Ernst Schering Research Found Workshop 2001; 30:105-18.	
		KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000 Nov 8;19(6):618-22.	
		KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.	
		KRIEG et al., Chapter 17: Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
		KROWN et al., Phase I trial with the interferon inducer polyI/poly-I-lysine (Poly ICL). Journal of Interferon Research. 1983; 3:281-90.	
	*	KUBY et al., ed., Chapter 13: Cytokines. Immunology: Second Edition. W.H. Freeman and Company, New York. 1994: 297-322.	
		KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.	
		KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40.	
		KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
		LAZARUS et al., Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics. 2003 Jan;81(1):85-91.	
		LeCLERC et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. 1997 Aug 1;179(2):97-106.	
	*	LEIBSON et al., Role of gamma-interferon in antibody-producing responses. Nature. 1984 Jun 28-Jul 4;309(5971):799-801.	
		LEIGH et al., Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. 2002 Nov 1;166(9):1212-7.	
		LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4.	
		LITZINGER et al., Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta. 1996 Jun 11;1281(2):139-49.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	12	of	19				

	*	LOTZ et al., Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus. J Rheumatol. 1987 Feb;14(1):42-5.	
		LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept7;45(7):333A.	
		LIU et al., Hygiene hypothesis: fact or fiction? J Allergy Clin Immunol. 2003 Mar;111(3):471-8.	
		LUKACS et al., Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol. 1994 May;10(5):526-32.	
		LUKACS et al., C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation. J Leukoc Biol. 1996 Nov;60(5):573-8.	
	*	MA et al., DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine. 2002 Sep 10;20(27-28):3263-71.	
	*	MARDH et al., Alternaria alternata as a cause of opportunistic fungal infections in man. Scand J Infect Dis Suppl. 1978;(16):36-40.	
		MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. 1999 Jul;11(7):1111-8.	
		McCLUSKIE et al., The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine. 2001 Mar 21;19(17-19):2657-60.	
		McCLUSKIE et al., The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol. 2001;21(1-3):103-20.	
		McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998 Nov 1;161(9):4463-6.	
		McCLUSKIE et al., CpG DNA as mucosal adjuvant. Vaccine. 2000;18: 231-7.	
		McCLUSKIE et al., The role of CpG in DNA vaccines. Springer Semin Immunopathol. 2000;22(1-2):125-32.	
		McCLUSKIE et al., Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol Med. 2000 Oct;6(10):867-77.	
		McCLUSKIE et al., Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 2000 Oct 15;19(4-5):413-22.	
		McCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22;19(7-8):950-7.	
	*	METZGER et al., Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci. 1996 Oct 31;795:100-15.	
		MILLIGAN et al., Current concepts in antisense drug design. J Med Chem. 1993 Jul 9;36(14):1923-37.	
	*	MOND et al., Recombinant interferon-gamma inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody. J Immunol. 1985 Oct;135(4):2513-7.	
		MOSMANN et al., The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996 Mar;17(3):138-46.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00		
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield		
Sheet	13	of	19					

		PADRID et al., CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma. Am J Respir Cell Mol Biol. 1998 Apr;18(4):453-62.	
		PARE et al., Lung mechanics following antigen challenge of Ascaris suum-sensitive rhesus monkeys. J Appl Physiol. 1976 Nov;41(5 Pt. 1):668-76.	
		PARK et al., The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J Allergy Clin Immunol. 2001 Oct;108(4):570-6.	
		PARRONCHI et al., Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors. J Immunol. 1999 Dec 1;163(11):5946-53.	
		PATTERSON et al., Inhibition of immunoglobulin E-mediated, antigen-induced monkey asthma and skin reactions by 5, 8, 11, 14-eicosatetraenoic acid. J Allergy Clin Immunol. 1981 Feb;67(2):146-52.	
		PAYETTE et al., History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord. 2001 Nov;1(3):241-7.	
		PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. Immunol Res. 1999;19(1):35-46.	
		PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
		PISETSKY et al., Immune activation by bacterial DNA: a new genetic code. Immunity. 1996 Oct;5(4):303-10.	
		RACILA et al., Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J Allergy Clin Immunol. 2005 Dec;116(6):1202-5.	
		RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40.	
		RAZ et al., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9519-23.	
		RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract Number 615.	
	*	REYNOLDS et al., Inhibition of B lymphocyte activation by interferon-gamma. J Immunol. 1987 Aug 1;139(3):767-73.	
		ROBINSON et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992 Jan 30;326(5):298-304.	
		ROY et al., Bacterial DNA in house and farm barn dust. J Allergy Clin Immunol. 2003 Sep;112(3):571-8.	
		SANDER et al., Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guerin. Immunology. 1995 Dec;86(4):512-8. Abstract Only.	
		SANDRASAGRA et al., Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):177-81.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	14	of	19				

		SANTELIZ et al., Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol. 2002 Mar;109(3):455-62. Exhibit 1041.	
		SCHWARTZ et al., Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. Am J Physiol. 1994 Nov;267(5 Pt 1):L609-17. Abstract Only.	
		SCHWARTZ et al., The role of endotoxin in grain dust-induced lung disease. Am J Respir Crit Care Med. 1995 Aug;152(2):603-8. Abstract Only.	
		SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol. 1999 Jul 1;163(1):224-31.	
	*	SIDMAN et al., Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature. 1984 Jun 28-Jul 4;309(5971):801-4.	
		SIEGRIST et al., Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine. 2004 Dec 16;23(5):615-22.	
		SILVERMAN et al., BCG vaccination and atopy--unfinished business? Lancet. 1997 Aug 9;350(9075):380-1.	
		SINGH et al., Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res. 2001 Oct;18(10):1476-9.	
		SJOLANDER et al., Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol. 1997 Apr 10;177(1):69-76.	
		SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
		SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7.	
		SPIEGELBERG et al., DNA-based approaches to the treatment of allergies. Curr Opin Mol Ther. 2002 Feb;4(1):64-71.	
		STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
		STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch 11: 241-64.	
		STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12.	
		STOKES et al., Rationale for new treatments aimed at IgE immunomodulation. Ann Allergy Asthma Immunol. 2004 Sep;93(3):212-7. Abstract Only.	
		STUART et al., Marketplace strategies: The asthma challenge -- Armed with a better understanding of the bad actors in the misguided immune response that causes allergies, companies hope to develop long-lasting treatments for asthma. Start-up. 1999 Apr; 12-20.	
		SUN et al. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998 Dec 21;188(12):2335-42.	
		SUN et al. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. Springer Semin Immunopathol. 2000;22(1-2):77-84.	
		SUR et al., Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol. 1999 May 15;162(10):6284-93.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00			
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield			
Sheet	15	of	19						

		THREADGILL et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. <i>Vaccine</i> . 1998 Jan;16(1):76-82.	
		TIGHE et al., Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. <i>J Allergy Clin Immunol</i> . 2000 Jul;106(1 Pt 1):124-34.	
		TOKUNGA, Response of the organism to DNA – With a focus on immunostimulatory DNA. <i>Kansen Ensho Meneki</i> . 2001 Autumn; 31(3): 1-12. Japanese. Exhibits 1048 and 1049.	
		TOMAI et al., Immunomodulating and antiviral activities of the imidazoquinoline S-28463. <i>Antiviral Res</i> . 1995 Nov;28(3):253-64.	
		TOURNOY et al., Is Th1 the solution for Th2 in asthma? <i>Clin Exp Allergy</i> . 2002 Jan;32(1):17-29.	
		TURNER et al., In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. <i>J Clin Invest</i> . 1996 Jan 15;97(2):381-7.	
		TURNER et al., Leukotriene D4 receptor antagonism reduces airway hyperresponsiveness in monkeys. <i>Pulm Pharmacol</i> . 1994 Feb;7(1):49-58.	
		TURNER et al., Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. <i>Am J Respir Crit Care Med</i> . 1994 May;149(5):1153-9.	
		TURNER et al., Characterization of a primate model of asthma using anti-allergy/anti-asthma agents. <i>Inflamm Res</i> . 1996 May;45(5):239-45.	
		VANDENBULCKE et al., The innate immune system and its role in allergic disorders. <i>Int Arch Allergy Immunol</i> . 2006;139(2):159-65. Abstract Only.	
		VERTHELYI et al., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. <i>Clin Immunol</i> . 2003 Oct;109(1):64-71.	
		VLASSOV et al., Oligonucleotides in cells and in organisms: pharmacological considerations. in <i>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</i> . 1991: 243-66.	
		WAGNER, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. <i>Curr Opin Microbiol</i> . 2002 Feb;5(1):62-9.	
	*	WALLNER et al., Immunotherapy with T-cell-reactive peptides derived from allergens. <i>Allergy</i> . 1994 May;49(5):302-8.	
		WEERATNA et al., CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. <i>FEMS Immunol Med Microbiol</i> . 2001 Dec;32(1):65-71.	
		WEERATNA et al., CpG DNA induces stronger immune responses with less toxicity than other adjuvants. <i>Vaccine</i> . 2000 Mar 6;18(17):1755-62.	
	*	WEERATNA et al., Optimization strategies for DNA vaccines. <i>Intervirology</i> . 2000;43(4-6):218-26.	
		WEERATNA et al., CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. <i>Immunol Cell Biol</i> . 2003 Feb;81(1):59-62.	
		WERNETTE et al., CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. <i>Vet Immunol Immunopathol</i> . 2002 Jan 15;84(3-4):223-36.	
	*	WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. <i>Ann N Y Acad Sci</i> . 1995 Nov 27;772:64-76.	
		WITT et al., Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. <i>Cancer Res</i> . 1993 Nov 1;53(21):5176-80.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00		
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield		
Sheet	16	of	19					

		WONG et al., Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1156-60.	
		WYATT et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1356-60.	
		YAMAMOTO, Cytokine production inducing action of oligo DNA. Rinsho Meneki. 1997; 29(9): 1178-84. Japanese. Exhibits 1050, 1047, and 1046.	
		YI et al. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol. 1998 Nov 1;161(9):4493-7.	
		YI et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol. 1998 Jun 15;160(12):5898-906.	
	*	ZHANG et al., Antigen- and isotype-specific immune responses to a recombinant antigen-allergen chimeric (RAAC) protein. J Immunol. 1993 Jul 15;151(2):791-9.	
		ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00		
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield		
Sheet	17	of	19					

	*	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625		ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003		CONFIRMATION NO.: 9416	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	18	of	19				

*	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
*	Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
*	Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
*	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
*	Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
				FILING DATE: December 22, 2003	CONFIRMATION NO.: 9416
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	19	of	19		

	*	Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
	*	Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
	*	Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005.	
	*	Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.